Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

Rescuing drug discovery: In vivo systems pathology and systems pharmacology

Publication files not online:

Author: Greef, J. van der · McBurney, R.N.
Type:article
Date:2005
Institution: TNO Kwaliteit van Leven
Source:Nature Reviews Drug Discovery, 12, 4, 961-967
Identifier: 238972
doi: doi:10.1038/nrd1904
Keywords: Pharmacology Health · Analytical research · 5' methoxyhydnocarpin · berberine · biological marker · ginseng extract · herbaceous agent · Hypericum extract · paroxetine · unclassified drug · article · bioinformatics · cardiovascular disease · clinical trial · cost benefit analysis · cost control · cost effectiveness analysis · data base · depression · drug approval · drug design · drug efficacy · drug indication · drug industry · drug information · drug marketing · drug research · drug response · drug safety · drug screening · drug targeting · growth inhibition · health care · health care cost · health program · human · in vivo study · non insulin dependent diabetes mellitus · nonhuman · patient compliance · prediction · prescription · priority journal · productivity · quantitative analysis · standard · system analysis · validation process · animal · diagnosis · economics · mass communication · review · Animals · Cost-Benefit Analysis · Diagnosis · Diffusion of Innovation · Drug Approval · Drug Design · Drug Evaluation · Drug Evaluation, Preclinical · Drug Industry · Humans

Abstract

The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss whether taking an in vivo systems approach to drug discovery and development could be the paradigm shift that rescues the industry.